市場調査レポート

商品コード

1619236

鎌状赤血球症治療市場規模、シェア、成長分析、治療別、最終用途別、地域別 - 産業別予測、2024～2031年

Sickle Cell Disease Treatment Market Size, Share, Growth Analysis, By Treatment (Blood Transfusion, Bone Marrow Transplant), By End-use (Hospitals, Specialty Clinics), By Region - Industry Forecast 2024-2031

出版日: 2024年12月20日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 767,811円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 898,194円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,028,577円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.87円

全表示
概要
目次

概要

サンプル依頼リストに入れる

鎌状赤血球症治療の世界市場規模は、2022年に21億米ドルと評価され、2023年の25億5,000万米ドルから2031年には120億3,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは4.1％で成長する見通しです。

鎌状赤血球症の世界の罹患率の上昇は、特にアフリカ、中東、インドといった遺伝的素因と認知度の低い地域において、効果的な治療に対する需要を大きく促進すると予想されます。新規治療法のための調査投資の拡大は、この分野の企業にとってチャンスとなります。さらに、認知度向上を目的とした政府や非営利団体による支援活動も、市場の展望を広げると思われます。革新的な医薬品の流入と治療パイプラインの拡充は、長期的には市場の成長を促進するものと思われます。しかし、新たな治療法の安全性への懸念、遺伝子治療に対する複雑な規制環境、継続的な認識不足といった課題が、2031年以降の世界鎌状赤血球症治療市場の進展を妨げる可能性があります。

北米
- 米国
- カナダ
欧州
- 英国
- ドイツ
- スペイン
- フランス
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2023年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2021-2023）

主要企業プロファイル

Novartis AG
Emmaus Medical, Inc.
Addmedica
Medunik USA
Global Blood Therapeutics, Inc.
Bristol Myers Squibb Co.
Sanofi SA
Bluebird Bio
Pfizer Inc.
Aruvant Sciences, Inc.
Glycomimetics, Inc.
Editas Medicine, Inc.
CRISPR Therapeutics
F. Hoffmann-La Roche Ltd
Janssen Pharmaceuticals
Merck & Co., Inc.
AstraZeneca
Gilead Sciences
Vertex Pharmaceuticals
Hemanext

結論と推奨事項

Product Code: SQMIG35D2091

Global Sickle Cell Disease Treatment Market size was valued at USD 2.10 billion in 2022 and is poised to grow from USD 2.55 billion in 2023 to USD 12.03 billion by 2031, growing at a CAGR of 4.1 % in the forecast period (2024-2031).

The rising global incidence of sickle cell disease is expected to significantly drive demand for effective treatments, particularly in regions like Africa, the Middle East, and India, where genetic predisposition and limited awareness prevail. Greater investment in research for novel therapies presents opportunities for companies in this sector. Additionally, supportive initiatives from governments and non-profits aimed at increasing awareness will broaden market prospects. The influx of innovative drugs and expanded treatment pipelines is set to enhance market growth in the long term. However, challenges such as safety concerns with new treatments, a complex regulatory environment for genetic therapies, and ongoing awareness deficits may hinder progress in the global sickle cell disease treatment market through 2031 and beyond.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sickle Cell Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sickle Cell Disease Treatment Market Segmental Analysis

Global Sickle Cell Disease Treatment Market is segmented by Treatment, End-use and region. Based on Treatment, the market is segmented into Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy (Hydroxyurea, Branded Products). Based on End-use, the market is segmented into Hospitals, Specialty Clinics, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sickle Cell Disease Treatment Market

The increasing prevalence of sickle cell disease is a significant driver for the global treatment market. Factors such as genetic factors and inadequate early detection have contributed to a sharp rise in cases worldwide. Regions such as Africa, India, and the Middle East are projected to have particularly high rates of sickle cell disease, presenting lucrative opportunities for treatment providers in these areas. As awareness and the need for effective treatment options grow, these markets are becoming increasingly attractive for healthcare companies focused on addressing the challenges posed by this condition and improving patient outcomes.

Restraints in the Global Sickle Cell Disease Treatment Market

A significant restraint in the Global Sickle Cell Disease Treatment market is the limited awareness and diagnosis among the public. Many individuals remain unaware of the symptoms associated with sickle cell disease, leading to delays in seeking medical attention and subsequent diagnosis. Furthermore, the inadequate diagnostic infrastructure in various regions exacerbates this issue, resulting in numerous cases either going undetected or being diagnosed too late for effective treatment. This combination of lack of awareness and insufficient diagnostic capabilities hinders the overall demand for sickle cell disease therapies, posing a challenge for growth in the treatment market moving forward.

Market Trends of the Global Sickle Cell Disease Treatment Market

The Global Sickle Cell Disease Treatment market is witnessing a burgeoning trend centered around collaborative efforts aimed at enhancing treatment accessibility. Varying availability of therapies across regions has hindered the adoption of innovative treatments, prompting partnerships among governments, non-profit organizations, and healthcare companies. These collaborations seek to improve the affordability and accessibility of therapies, thereby promoting patient access and increasing market penetration. As stakeholders unite to address the disparities in treatment availability, the market is poised for significant growth, leading to improved patient outcomes and revenue generation in the long run, while fostering a more equitable healthcare landscape for sickle cell disease management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies

Global Sickle Cell Disease Treatment Market Size by Treatment & CAGR (2024-2031)

Market Overview
Bone Marrow Transplant
Blood Transfusion
Pharmacotherapy
- Hydroxyurea
- Branded Products

Global Sickle Cell Disease Treatment Market Size by End-use & CAGR (2024-2031)

Market Overview
Hospitals
Specialty Clinics
Others

Global Sickle Cell Disease Treatment Market Size & CAGR (2024-2031)

North America, (Treatment, End-use)
- US
- Canada
Europe, (Treatment, End-use)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific, (Treatment, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America, (Treatment, End-use)
- Brazil
- Rest of Latin America
Middle East & Africa, (Treatment, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emmaus Medical, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Addmedica
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medunik USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Global Blood Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aruvant Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glycomimetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Editas Medicine, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hemanext
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

鎌状赤血球症治療市場規模、シェア、成長分析、治療別、最終用途別、地域別 - 産業別予測、2024～2031年

Sickle Cell Disease Treatment Market Size, Share, Growth Analysis, By Treatment (Blood Transfusion, Bone Marrow Transplant), By End-use (Hospitals, Specialty Clinics), By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

鎌状赤血球症治療市場規模：治療別

鎌状赤血球症治療市場規模：最終用途別

鎌状赤血球症治療市場規模：地域別